# Mitroflow DL Post Approval Study- North America

Study · id `cardio:ct-nct02351726` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02351726](<https://clinicaltrials.gov/study/NCT02351726>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02351726

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.

## Technical summary

Registry record NCT02351726. Allocation not applicable; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2019-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 186 participants (enrolled count; ClinicalTrials.gov record NCT02351726, source copy `cardio:ctgov-nct02351726-2020-02-20`, retrieved 2026-10-26)
- Started: 2015-03 (actual) (ClinicalTrials.gov record NCT02351726, source copy `cardio:ctgov-nct02351726-2020-02-20`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (actual) (ClinicalTrials.gov record NCT02351726, source copy `cardio:ctgov-nct02351726-2020-02-20`, retrieved 2026-10-26)
- Completion: 2019-12-31 (actual) (ClinicalTrials.gov record NCT02351726, source copy `cardio:ctgov-nct02351726-2020-02-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02351726, source copy `cardio:ctgov-nct02351726-2020-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02351726-2020-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Mitroflow DL Post Approval Study- North America
- Condition: Aortic Stenosis
- Condition: Aortic Regurgitation
- Condition: Aortic Valve Insufficiency
- Condition: Heart Valve Diseases
- Condition: Cardiovascular Abnormalities
- Condition: Cardiovascular Diseases
- Condition: Congenital Abnormalities
- Condition: Heart Diseases
- Condition: Pathological Conditions, Anatomical
- Intervention (Device): Mitroflow DL
- Lead sponsor: LivaNova
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: LivaNova (`cardio:org-livanova`)

## Provenance

Content hash: 60dbbce3a36b0f58714652761d95f6c49e44d0acccd9100990dd1d0d8ce9bc16
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
